EUVIMED · CrossrefZeitschrift
Investigational New Drugs
ISSN 0167-6997 · Springer Science and Business Media LLC
Neueste Artikel
Novel EGFR tyrosine kinase inhibitors exhibiting intrinsic fluorescence
The novel agent VP79s synergistically enhances venetoclax activity in multiple myeloma cells
Parthenolide enhances imatinib activity in gastrointestinal stromal tumor models through stress-associated apoptosis
Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic cancer treated with gemcitabine and nab-paclitaxel: an exploratory biomarker analysis of the GENESECT study
Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer
Qishen Yiqi Dripping Pills ameliorate doxorubicin-induced cardiotoxicity: a study based on bioinformatics and experimental verification
Comparative efficacy of CLDN18.2-directed regimens in advanced gastric/gastroesophageal junction adenocarcinoma: a meta-analysis of single-arm trials
First-in-human phase I study of DT-9081, a selective EP4 receptor antagonist, in advanced solid tumors
Correction to: Prostate cancer cells’ growth is decreased by novel MYC inhibitors
Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study
Allogeneic hematopoietic stem cell transplantation with liposomal mitoxantrone conditioning for extramedullary leukemia
A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors
Clinical features, diagnosis and prognosis of nivolumab-associated fulminant type 1 diabetes
Characterizing the post-market safety profile of cemiplimab: a pharmacovigilance study of the FDA adverse events reporting system database
Characterizing the post-market safety profile of lazertinib: a pharmacovigilance study of the FDA Adverse Events Reporting System Database
Clinical features, treatment and outcomes of pembrolizumab induced autoimmune hemolytic anemia
Clinical features, treatment and outcomes of dabrafenib-associated uveitis
Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor–relapsed tumors
Clinical characteristics, treatment and prognosis of pembrolizumab induced myocarditis
Beyond the obvious: targeting the SLC transportome and non-canonical drug transport mechanisms in cancer therapy
Discovery of potent CRBN-recruiting epidermal growth factor receptor (EGFR) degraders in vitro
A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors
From development to clinical success: the journey of established and next-generation BTK inhibitors
Retrospective analysis of clinical features of nivolumab-induced immune-related pancreatitis
The up-regulated expression level of deubiquitinating enzyme USP46 induces the apoptosis of A549 cells by TRAF6
Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity
Immunotherapy in thymic epithelial tumors: an attractive dilemma
A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer
Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study
Gremlin1: a BMP antagonist with therapeutic potential in Oncology
Jahrgänge
2026 · 242025 · 1012024 · 842023 · 962022 · 1572021 · 1882020 · 1942019 · 1442018 · 1322017 · 992016 · 902015 · 1452014 · 1482013 · 1902012 · 2862011 · 1792010 · 1152009 · 762008 · 682007 · 752006 · 662005 · 722004 · 512003 · 462002 · 602001 · 452000 · 381999 · 421998 · 531997 · 421996 · 521995 · 581994 · 571993 · 521992 · 651991 · 731990 · 941989 · 511988 · 561987 · 55
EUVIMED